EA005367B1 - Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения - Google Patents

Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения Download PDF

Info

Publication number
EA005367B1
EA005367B1 EA200101213A EA200101213A EA005367B1 EA 005367 B1 EA005367 B1 EA 005367B1 EA 200101213 A EA200101213 A EA 200101213A EA 200101213 A EA200101213 A EA 200101213A EA 005367 B1 EA005367 B1 EA 005367B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
hydrogen
optionally substituted
alkyl
covalent bond
Prior art date
Application number
EA200101213A
Other languages
English (en)
Russian (ru)
Other versions
EA200101213A1 (ru
Inventor
Майкл С. Саут
Квингпинг Зенг
Мелвин Л. Руппел
Джон Дж. Парлоу
Эштон Т. II Хамме
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200101213A1 publication Critical patent/EA200101213A1/ru
Publication of EA005367B1 publication Critical patent/EA005367B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77Hydrazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
EA200101213A 1999-05-19 2000-05-15 Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения EA005367B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13481199P 1999-05-19 1999-05-19
PCT/US2000/008220 WO2000069826A1 (fr) 1999-05-19 2000-05-15 Pyridones aryle et heteroaryle polycycliques substituees utilisees pour l'inhibition selective de la cascade de coagulation

Publications (2)

Publication Number Publication Date
EA200101213A1 EA200101213A1 (ru) 2002-04-25
EA005367B1 true EA005367B1 (ru) 2005-02-24

Family

ID=22465131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101213A EA005367B1 (ru) 1999-05-19 2000-05-15 Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения

Country Status (21)

Country Link
EP (1) EP1178964A1 (fr)
JP (1) JP2002544260A (fr)
KR (1) KR20010113970A (fr)
CN (1) CN1378534A (fr)
AR (1) AR029635A1 (fr)
AU (1) AU771928B2 (fr)
BR (1) BR0011272A (fr)
CA (1) CA2373509A1 (fr)
CZ (1) CZ20014117A3 (fr)
EA (1) EA005367B1 (fr)
HU (1) HUP0201996A3 (fr)
IL (1) IL146244A0 (fr)
MX (1) MXPA01011805A (fr)
MY (1) MY138303A (fr)
NO (1) NO20015606L (fr)
NZ (1) NZ514875A (fr)
PL (1) PL352403A1 (fr)
SK (1) SK15862001A3 (fr)
UY (1) UY26154A1 (fr)
WO (1) WO2000069826A1 (fr)
ZA (2) ZA200109340B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
WO2001068605A1 (fr) 2000-03-13 2001-09-20 Pharmacia Corporation Benzenes polycycliques substitues aryle et heteroaryle utiles pour l'inhibition selective de la cascade de coagulation
JP2004505014A (ja) 2000-04-05 2004-02-19 ファルマシア・コーポレーション 凝血カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換された4−ピロン類
JP2004505013A (ja) 2000-04-05 2004-02-19 ファルマシア・コーポレーション 凝固カスケードを選択的に阻害するのに有用な多環式アリール及びヘテロアリール置換4−ピリドン類
WO2001079195A2 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Nouveaux inhibiteurs de thrombine de type non covalent
US20040171616A9 (en) 2000-04-17 2004-09-02 South Michael S. Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001217827A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP2004517074A (ja) 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
EP1432687A2 (fr) 2001-10-03 2004-06-30 Pharmacia Corporation Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
WO2003048127A1 (fr) * 2001-12-04 2003-06-12 Corvas International, Inc. Inhibiteurs non covalents heterocycliques aromatiques de l'urokinase et de la formation de vaisseaux sanguins
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001338A1 (fr) * 1995-06-27 1997-01-16 Merck & Co., Inc. Inhibiteurs de la thrombine a base de pyridinone
WO1997030708A1 (fr) * 1996-02-22 1997-08-28 Merck & Co., Inc. Inhibiteurs de pyridinone thrombine
WO1998016525A1 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
WO1998042342A1 (fr) * 1997-03-24 1998-10-01 Merck & Co., Inc. Inhibiteurs de thrombine
WO1998047876A1 (fr) * 1997-04-24 1998-10-29 Akzo Nobel N.V. Derives heterocycliques et leur utilisation en tant qu'agents antithrombotiques
WO1999000126A1 (fr) * 1997-06-26 1999-01-07 Eli Lilly And Company Agents antithrombotiques
WO1999011267A1 (fr) * 1997-09-05 1999-03-11 Merck & Co., Inc. Inhibiteurs de thrombine a base de pyrazinone
US6037356A (en) * 1997-11-26 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
WO2000018762A1 (fr) * 1998-09-28 2000-04-06 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000026210A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000026211A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000032574A1 (fr) * 1998-11-27 2000-06-08 Sanofi-Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001338A1 (fr) * 1995-06-27 1997-01-16 Merck & Co., Inc. Inhibiteurs de la thrombine a base de pyridinone
WO1997030708A1 (fr) * 1996-02-22 1997-08-28 Merck & Co., Inc. Inhibiteurs de pyridinone thrombine
WO1998016525A1 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
WO1998042342A1 (fr) * 1997-03-24 1998-10-01 Merck & Co., Inc. Inhibiteurs de thrombine
WO1998047876A1 (fr) * 1997-04-24 1998-10-29 Akzo Nobel N.V. Derives heterocycliques et leur utilisation en tant qu'agents antithrombotiques
WO1999000126A1 (fr) * 1997-06-26 1999-01-07 Eli Lilly And Company Agents antithrombotiques
WO1999011267A1 (fr) * 1997-09-05 1999-03-11 Merck & Co., Inc. Inhibiteurs de thrombine a base de pyrazinone
US6037356A (en) * 1997-11-26 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
WO2000018762A1 (fr) * 1998-09-28 2000-04-06 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000026210A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000026211A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2000032574A1 (fr) * 1998-11-27 2000-06-08 Sanofi-Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANDERSON P. E. J. ET AL.: "L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor". BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 7, no. 12, 17 June 1997 (1997-06-17), pages 1497-1500, XP004136244, ISSN: 0960-894X, the whole document *

Also Published As

Publication number Publication date
SK15862001A3 (sk) 2002-08-06
KR20010113970A (ko) 2001-12-28
CA2373509A1 (fr) 2000-11-23
UY26154A1 (es) 2000-12-29
NZ514875A (en) 2004-10-29
AR029635A1 (es) 2003-07-10
EA200101213A1 (ru) 2002-04-25
CZ20014117A3 (cs) 2002-05-15
MXPA01011805A (es) 2003-09-04
JP2002544260A (ja) 2002-12-24
ZA200109340B (en) 2004-05-26
IL146244A0 (en) 2002-07-25
MY138303A (en) 2009-05-29
CN1378534A (zh) 2002-11-06
BR0011272A (pt) 2002-05-07
NO20015606D0 (no) 2001-11-16
ZA200400449B (en) 2004-11-24
AU4797300A (en) 2000-12-05
HUP0201996A2 (en) 2002-09-28
AU771928B2 (en) 2004-04-08
EP1178964A1 (fr) 2002-02-13
WO2000069826A1 (fr) 2000-11-23
HUP0201996A3 (en) 2002-12-28
PL352403A1 (en) 2003-08-25
NO20015606L (no) 2002-01-21

Similar Documents

Publication Publication Date Title
EA005367B1 (ru) Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения
JP4199309B2 (ja) 新規アセトアミド誘導体およびプロテアーゼ阻害
JP3176365B2 (ja) ベンゼンスルホンアミド誘導体
KR100416111B1 (ko) 아미딘 화합물
US6180627B1 (en) Antithrombotic agents
AU775701B2 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
JP4939401B2 (ja) TAFIa阻害剤として用いるイミダゾール誘導体
AU730127B2 (en) Sulfamide-metalloprotease inhibitors
EA004867B1 (ru) Замещенные пиримидиноновые соединения, композиция и способ лечения, ингибирования или предупреждения тромботических состояний у млекопитающих
JP2000502330A (ja) メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体
PL198032B1 (pl) Pochodne amidów, sposób ich wytwarzania, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
KR20150018788A (ko) 혈전색전성 질환의 치료를 위한 인자 xia 억제제로서 치환된 피롤리딘
US6689794B2 (en) Aromatic sulfone hydroxamates and their use as protease inhibitors
EP2138482A1 (fr) Composé hétérocyclique bicyclique
JP2005515976A (ja) 新規メタロプロテイナーゼ阻害剤
JP2004512267A (ja) 第Xa因子のラクタム系阻害剤および方法
US7001899B2 (en) Interleukin converting enzyme inhibitors
JP2005514332A (ja) 凝固カスケードの選択阻害に有用な6員不飽和複素環式化合物
CA2021740A1 (fr) Peptidyl aminodiol inhibiteur de la remine
US5296494A (en) Pyrrolidine compounds having thromboxane A2 receptor antagonistic activity and thromboxane A2 synthase inhibiting activity
JP2006515840A (ja) トロンビンおよびxa因子の阻害剤としてのピロリジン−2−オン誘導体
EP1562928A1 (fr) Acides hydroxamiques a groupe sulphone aromatique et leur utilisation comme inhibiteurs de protease
US20040167182A1 (en) Hydroxamic acid and amide compounds and their use as protease inhibitors
JP2009534310A (ja) レニン阻害剤
US6417203B1 (en) Antithrombotic agents

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU